Promises
3 promises
Promise Tracker
0 delivered, 0 close, 3 missed.
View Promises →Gland Pharma Limited — Q2 FY24
Gland Pharma reported consolidated revenue of INR 1,373.4 crore in Q2 FY24, up 32% YoY, driven by Cenexi acquisition and US market recovery.
neutral
medium
✓ Verified against BSE filing
2-Minute Summary
✦ AI-Generated from Full Transcript
Gland Pharma reported consolidated revenue of INR 1,373.4 crore in Q2 FY24, up 32% YoY, driven by Cenexi acquisition and US market recovery. EBITDA grew 8% YoY to INR 320.5 crore, but margin contracted to 23% (down 500 bps YoY) due to Cenexi's seasonal shutdown and fixed costs. PAT fell 20% YoY to INR 194.1 crore. Base business EBITDA margin improved to 34% (vs 28% YoY) on stable US pricing and volume growth. Cenexi contributed INR 358.8 crore revenue (2-month) with negative EBITDA. Management guided for steady sequential growth, base EBITDA margins of 30-32%, and EUR 60 million investment in Cenexi over 18 months. Risk: Cenexi's annual summer shutdown may continue to distort quarterly results.
ग्लैंड फार्मा ने दूसरी तिमाही में 1,373.4 करोड़ रुपये का कारोबार किया, जो पिछले साल से 32% ज्यादा है। यह बढ़ोतरी सीनेक्सी कंपनी खरीदने और अमेरिकी बाजार में सुधार से हुई। कमाई (EBITDA) 320.5 करोड़ रुपये रही, जो 8% बढ़ी, लेकिन मुनाफा दर 23% पर आ गई (पिछले साल से 5% कम)। इसकी वजह सीनेक्सी की छुट्टियों और फिक्स्ड खर्चे हैं। शुद्ध मुनाफा (PAT) 194.1 करोड़ रुपये रहा, जो 20% घटा। अमेरिका में कीमतें स्थिर रहने और बिक्री बढ़ने से मुख्य कारोबार की मुनाफा दर 34% (पिछले साल 28%) रही। सीनेक्सी ने 358.8 करोड़ रुपये का कारोबार किया, लेकिन उसका मुनाफा नकारात्मक रहा। कंपनी का कहना है कि आगे धीरे-धीरे बढ़ोतरी होगी, मुख्य कारोबार की मुनाफा दर 30-32% रहेगी, और सीनेक्सी में 18 महीने में 60 मिलियन यूरो निवेश करेगी। खतरा: सीनेक्सी की गर्मी की छुट्टियां हर तिमाही के नतीजों को प्रभावित कर सकती हैं।
Promises0 met · 3 missedRisks4 trackedTranscriptfull text
Research workspace
Focused Modules
Risks
4 risks
Risk Intelligence
Cenexi annual summer shutdown impact
View Risks →
Transcript
Full text
Call Transcript
Full transcript text is available on this route.
Read Transcript →Quarter Snapshot
US Revenue Growth (QoQ)
22%
+22% QoQ
US market revenue increased 22% sequentially, driven by new launches and volume growth.
Base Business EBITDA Margin
34%
+600 bps YoY
Ex-Cenexi EBITDA margin improved to 34% from 28% in Q2 FY23, aided by cost efficiencies.
Cenexi Revenue (2 months)
INR 358.8 Cr
N/A
Cenexi revenue for two months (Aug-Sep) was INR 358.8 crore, with negative EBITDA due to shutdown.
ANDA Approvals (Q2)
5
+5 QoQ
Received 5 ANDA approvals in Q2; cumulative 275 approved ANDAs as of Sep 2023.
What Changed vs Last Quarter
NEW
Base business EBITDA margin target of 30-32%
Management expects base business EBITDA margins to remain in the 30-32% range, with potential slight decline as lower-margin Enoxaparin supplies resume.
NEW
Cenexi revenue run rate of EUR 50-55 million per quarter
CFO guided that Cenexi's normalized quarterly revenue should be around EUR 50-55 million on a full quarter basis.
NEW
EUR 60 million investment in Cenexi over 12-18 months
Planned investment of EUR 60 million in CapEx and working capital to enhance capacity and operational efficiencies at Cenexi.
NEW
Steady sequential revenue growth for base business
Management expects steady quarter-on-quarter growth in the base business, driven by new launches and volume expansion.
DROPPED
U.S. sequential growth expected
Management expects steady sequential growth in U.S. revenue, with no decline anticipated.
DROPPED
Cenexi margin improvement in 1-2 quarters
Cenexi EBITDA margins are expected to improve in the next 1-2 quarters through operational efficiencies.
DROPPED
Enoxaparin run rate to normalize from Q2
Enoxaparin sales are expected to pick up from next quarter as inventory rationalization ends.
DROPPED
40+ product launches planned for FY24
Total product launches in FY24 will be higher than normal due to relaunches, exceeding 40.
NEW RISK
Enoxaparin pricing and volume pressure in ROW markets
ROW revenue declined 9% QoQ due to lower Enoxaparin volumes and pricing pressure from competition, with management noting very low margins.
NEW RISK
Cenexi margin improvement timeline uncertain
Management declined to provide a timeline for Cenexi reaching 13-15% EBITDA margins, citing early stage of integration.
NEW RISK
Potential dilution from milestone income volatility
Milestone income (5% of ex-Cenexi revenue in Q2) can fluctuate between 5-10%, impacting quarterly comparability.
RISK GONE
Cenexi integration delays
Integration of Cenexi may face operational challenges, delaying synergy realization and margin improvement.
RISK GONE
U.S. pricing pressure from Chinese competitors
Aggressive pricing by Chinese players in injectables could pressure margins, though management sees recent stabilization.
RISK GONE
Dependence on enoxaparin recovery
Enoxaparin sales recovery is critical for U.S. growth; any further delays could impact revenue.
Fast read
Guidance and risk preview
Management expects base business EBITDA margins to remain in the 30-32% range, with potential slight decline as lower-margin Enoxaparin supplies re...
Cenexi's annual summer shutdown (4 weeks in France, 3 in Belgium) will continue to cause revenue loss and negative EBITDA in Q2 each year.
View Risks →